Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.

Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev

Eli Lilly

The FDA has approved the use of Eli Lilly And Co's (NYSE:LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ:PODD) insulin management systems. Lyumjev, approved by the FDA in June 2020, is a formulation of insulin lispro to speed insulin absorption into the bloodstream.

FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced FDA clearance for use of Eli Lilly and Company's (NYSE: LLY) Lyumjev® (insulin lispro-aabc injection) 100 units/mL with Insulet's Omnipod® Insulin Management System and Omnipod DASH® Insulin Management System. Insulet is the only insulin pump manufacturer in the United States to obtain this indication, pro

Insulet Announces FDA Clearance of Lyumjev® Rapid-Acting Insulin for Use with Omnipod® Products in the United States

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented the Omnipod DASH® Insulin Management System (Omnipod DASH) to healthcare providers attending the virtual Australasian Diabetes Congress. Insulet expects to begin taking customer orders for Omnipod DASH by the end of August. “As part of our ongoing efforts to bring Omnipod technology to more people l

Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress

Insulet (PODD) reports better-than-expected revenues for second-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Insulet (PODD) Q2 Earnings Miss Estimates, Revenues Beat

Insulet Corporation (PODD) CEO Shacey Petrovic on Q2 2021 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Q2 Earnings Lag Estimates

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2021. Second Quarter Financial Highlights: Second quarter 2021 revenue of $263.2 million, up 16.3%, or 12.5% in constant currency1, compared to $226.3 million in the prior year, within the guidance range of 10% to 14% on a constant currency basis

Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year

DexCom

Lululemon Athletica

Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.

3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Insulet (PODD) Q2 Earnings Expected to Decline

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2021 on August 5, 2021 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor R

Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021

Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.

Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced promising results from its latest pivotal trial for the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in very young children. Omnipod 5, the world's first tubeless, wearable automated insulin delivery (AID) system that continuously adapts insulin delivery based on glucose levels and trends

Insulet's Omnipod® 5 Automated Insulin Delivery System Pivotal Studies Demonstrate Improved Outcomes Across the Lifespan from Ages 2 to 70 years

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its schedule of events for the American Diabetes Association (ADA) Virtual 81st Scientific Sessions June 25 – 29, 2021. Following the release of its initial pivotal trial results in March, Insulet will present new clinical outcomes data for preschool children with type 1 diabetes using the Omnipod 5

Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System

Autodesk

Amazon

DocuSign

Humana

ICICI Bank Ltd.

Workday

Lone Pine Capital, the hedge fund founded by Steve Mandel (Trades, Portfolio) in 1997, disclosed its first-quarter portfolio earlier this week.

Top 5 1st-Quarter Trades of Steve Mandel's Lone Pine

Insulet's (PODD) Q1 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Insulet (PODD) Q1 Earnings Fall Shy of Estimates, Revenues Beat

Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2021 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of -100.00% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Reports Break-Even Earnings for Q1

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2021. First Quarter Financial Highlights: First quarter 2021 revenue of $252.3 million, up 27.4%, or 23.9% in constant currency1, compared to $198.0 million in the prior year, achieving high end of guidance of 20% to 24% on a constant currency b

Insulet Reports First Quarter 2021 Revenue Increase of 27% Year-Over-Year

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the virtual BofA Securities 2021 Health Care Conference on Wednesday, May 12, 2021 at 4:15 p.m. (Eastern Time). To listen to the live audio webcast of the presentation, please visit http://investors.insulet.com. A replay of the audio webcast will also be available following the even

Insulet to Present at BofA Securities 2021 Virtual Healthcare Conference

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the publication of its 2020 Sustainability Report. The report, which includes Insulet's first comprehensive sustainability strategy and materiality assessment, highlights the Company's areas of focus and performance on Environmental, Social, and Governance (ESG) issues. “As a leading medical device

Insulet 2020 Sustainability Report Conveys Strategy to Deliver Growth with Purpose

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the pricing of a $500 million senior secured term loan B facility (the term facility) and a $60 million senior secured revolving facility (the revolving facility, and together with the term facility, the credit facilities). The Company expects that loans under the term facility will be issued at 99.7

Insulet Announces Pricing of New Senior Secured Credit Facilities

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that it has launched the syndication of new senior secured credit facilities, comprised of a senior secured revolving facility and a senior secured term loan B facility (the senior secured credit facilities). The closing of the senior secured credit facilities and the terms thereof are subject to obt

News for Insulet Stock (PODD)